[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Bonvalot S, Vanel D, Terrier P, Robert C, Le Cesne A, Le Péchoux C: [Management of recurrent soft tissue sarcoma of the retroperitoneum]. Bull Cancer; 2004 Nov;91(11):845-52
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of recurrent soft tissue sarcoma of the retroperitoneum].
  • [Transliterated title] Traitement des récidives des sarcomes rétro-péritonéaux.
  • Local recurrence is the determinant of tumor-related mortality in retroperitoneal sarcomas because death often occurs as a result of local progression mostly without synchronous metastasis.
  • Complete resection of the lesion and surgical margins status are the only therapeutic factors significantly associated with local control.
  • Further outcome improvements need multimodal therapy since prognosis of these recurrences is poor with lower rates of complete resection and higher grade of malignancy than primary.
  • Chemotherapy protocols may enhance local and systemic outcome and can reduce the volume of high grade tumors and therefore allow a higher rate of complete resection.
  • Isolated pelvic perfusion with local high doses chemotherapy is under investigation.
  • Surgical excision of lung metastases should remain the treatment of choice, if preoperative evaluation indicates that complete clearance of the metastases is possible.
  • Intra-operative chemotherapy after cyto-reductive surgery for the treatment of sarcomatosis is disappointing and complete surgery remains the cornerstone of the treatment with best results for low grade sarcomatosis.
  • Adequate management at the time of primary presentation is likely to afford the best chance for long-term survival.
  • [MeSH-major] Neoplasm Recurrence, Local / therapy. Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Combined Modality Therapy. Humans

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15582888.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 53
  •  go-up   go-down


2. Windham TC, Pisters PW: Retroperitoneal sarcomas. Cancer Control; 2005 Jan-Feb;12(1):36-43
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal sarcomas.
  • BACKGROUND: The evaluation and treatment of retroperitoneal sarcomas are challenging because the tumors are relatively rare and frequently present with advanced disease in an anatomically complex location.
  • METHODS: We reviewed the literature on experience in the management of retroperitoneal sarcomas, and we present our own experience in the treatment of these tumors.
  • Due to a lack of associated symptoms, retroperitoneal sarcomas smaller than 5 cm are rare.
  • Computed tomography is the most useful tool in the evaluation of retroperitoneal tumors.
  • Surgery, radiation therapy, and chemotherapy are treatment options, but the most important factor in the treatment of primary tumors is complete surgical resection.
  • The role of neoadjuvant and adjuvant therapies is not defined and should be considered within the context of clinical trials.
  • CONCLUSIONS: Early referral of patients with retroperitoneal soft tissue tumors will help to ensure that they will receive the benefits of multidisciplinary evaluation and treatment of their disease and ready access to clinical trials.
  • [MeSH-major] Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / surgery. Prognosis. Radiotherapy / methods. Retroperitoneal Space / pathology. Retroperitoneal Space / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668651.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 71
  •  go-up   go-down


3. Gholami S, Jacobs CD, Kapp DS, Parast LM, Norton JA: The value of surgery for retroperitoneal sarcoma. Sarcoma; 2009;2009:605840
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of surgery for retroperitoneal sarcoma.
  • Introduction. Retroperitoneal sarcomas are uncommon large malignant tumors.
  • Methods. Forty-one consecutive patients with localized retroperitoneal sarcoma were retrospectively studied.
  • Thirty-eight patients had an initial complete resection; 15 (37%) developed recurrent sarcoma and 12 (80%) had a second complete resection.
  • Radiation therapy or chemotherapy had no significant impact on overall or recurrence-free survival.
  • Complete surgical resection is the treatment of choice for patients with initial and locally recurrent retroperitoneal sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):859-68 [8622034.001]
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] Curr Treat Options Oncol. 2000 Aug;1(3):274-8 [12057171.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):468-73 [12393986.001]
  • [Cites] Arch Surg. 2003 Mar;138(3):248-51 [12611567.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1 [14501502.001]
  • [Cites] Oncology. 2003;65 Suppl 2:80-4 [14586155.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):483-90 [15078637.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):669-75 [16003776.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):508-17 [16491338.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):234-8 [17081725.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):31-7 [19047280.001]
  • [Cites] Ann Surg. 1990 Jul;212(1):51-9 [2363604.001]
  • [Cites] Arch Surg. 1995 Oct;130(10):1104-9 [7575124.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):137-42 [19106689.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • (PMID = 19826633.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009337
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2760213
  •  go-up   go-down


Advertisement
4. Farina GP, Baccoli A, Pani C, Cagetti M: [Retroperitoneal sarcomas: our experience]. G Chir; 2004 May;25(5):163-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retroperitoneal sarcomas: our experience].
  • BACKGROUND: Retroperitoneal soft tissues sarcomas (STS) are relatively uncommon and constitute a difficult management problem.
  • Although surgical resection is often difficult or impossible, current chemotherapy is not effective and radiation is limited by toxicity to adjacent structures.
  • PATIENTS AND METHODS: Fifteen patients with retroperitoneal STS were admitted and treated between January 1990 and January 2003, and prospectively followed.
  • Patient, tumor, and treatment variables were analyzed for disease-specific and disease-free survival.
  • RESULTS: The patients with unresectable disease, incomplete resection, and high-grade tumors presented significantly reduced survival time.
  • Because death often occurs as a result of local progression in retroperitoneal liposarcomas, it is possible that incomplete resection may be beneficial in this histologic type.
  • Complete surgical resection is the most effective modality for the treatment of retroperitoneal sarcomas.
  • [MeSH-major] Retroperitoneal Neoplasms / surgery. Sarcoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15382473.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Katz MH, Choi EA, Pollock RE: Current concepts in multimodality therapy for retroperitoneal sarcoma. Expert Rev Anticancer Ther; 2007 Feb;7(2):159-68
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in multimodality therapy for retroperitoneal sarcoma.
  • Radical surgical resection currently represents the most effective therapy for patients with retroperitoneal sarcoma.
  • Unfortunately, margin-negative resection often mandates extirpation of multiple retroperitoneal viscera, and such operations are nonetheless fraught with high rates of locoregional recurrence.
  • In an attempt to improve local control and ultimately survival, adjuvant strategies of radiation and chemotherapy have been increasingly employed, with promising results.
  • In this article, we review the current literature pertaining to the diagnosis, staging and treatment of retroperitoneal sarcoma and demonstrate the critical need for future large, multi-institutional studies to advance our knowledge of this uncommon disease.
  • [MeSH-major] Combined Modality Therapy / trends. Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Chemotherapy, Adjuvant / trends. Humans. Radiotherapy, Adjuvant / methods. Radiotherapy, Adjuvant / trends

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17288527.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 49
  •  go-up   go-down


6. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal sarcomas.
  • The approach to the management of retroperitoneal tumors begins with a complete history and physical examination.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • If the diagnosis is sarcoma, additional tests necessary for staging include plain chest radiography and evaluation of the liver by either CT scan or magnetic resonance imaging (MRI).
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


7. Cheifetz R, Catton CN, Kandel R, O'Sullivan B, Couture J, Swallow CJ: Recent progress in the management of retroperitoneal sarcoma. Sarcoma; 2001;5(1):17-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent progress in the management of retroperitoneal sarcoma.
  • Retroperitoneal sarcomas (RPS) are rare tumours that typically present late and carry a poor prognosis even following grossly complete resection.
  • In an attempt to improve the outlook for patients with RPS, sarcoma specialists have employed various adjuvant therapies, including extermal beam radiation, intraoperative radiation, brachyradiation and systemic chemotherapy.
  • This article reviews the presentation and prognosis of RPS, and focuses on the results of new treatment strategies compared with conventional management.A Medline search of the English literature was performed to identify all retrospective and prospective reports relating to the management of adult RPS published since 1980.
  • Series that did not analyse RPS separately from other intra-abdominal or extra-abdominal sarcomas or other malignancies were excluded, and information on investigation, presentation, prognostic factors, treatment and outcome was extracted from the remaining reports.
  • Survival and local control data were collected from reports that contained at least 30 cases of RPS (n = 31).While surgical resection remains the cornerstone of treatment for RPS, the majority of patients will relapse and die from sarcoma within 5 years of resection.
  • Possible reasons for the failure of conventional treatment are discussed, and alternative strategies designed to overcome these obstacles are presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1985 Sep;150(3):376-80 [4037201.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):278-83 [1906369.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):825-30 [6735766.001]
  • [Cites] Am J Surg Pathol. 1983 Apr;7(3):269-80 [6837835.001]
  • [Cites] Clin Oncol. 1982;8(3):257-63 [7140054.001]
  • [Cites] Cancer. 1981 May 1;47(9):2147-52 [7226108.001]
  • [Cites] J Surg Oncol. 1981;17(1):1-7 [7230826.001]
  • [Cites] Semin Oncol. 1981 Jun;8(2):180-4 [7256293.001]
  • [Cites] Arch Surg. 1995 Oct;130(10):1104-9 [7575124.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):211-44 [8000998.001]
  • [Cites] J Surg Oncol. 1994 Aug;56(4):213-6 [8057644.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1091-9 [8262833.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):637-42 [8299085.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] J Surg Oncol. 1996 May;62(1):49-56 [8618402.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] Ann Surg. 1990 Jul;212(1):51-9 [2363604.001]
  • [Cites] Br J Radiol. 1990 May;63(749):346-8 [2379060.001]
  • [Cites] Surgery. 1989 Oct;106(4):725-32; discussion 732-3 [2799648.001]
  • [Cites] Arch Surg. 1989 Oct;124(10):1168-73 [2802979.001]
  • [Cites] Acta Radiol Oncol. 1985 Jul-Aug;24(4):305-10 [2994385.001]
  • [Cites] Eur J Surg Oncol. 1986 Mar;12(1):29-33 [3007219.001]
  • [Cites] Surgery. 1988 Feb;103(2):247-56 [3124281.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):18-25 [3275748.001]
  • [Cites] Surgery. 1985 Mar;97(3):316-25 [3975851.001]
  • [Cites] Eur J Cancer. 1996 Apr;32A(4):622-6 [8695264.001]
  • [Cites] Cancer Treat Res. 1996;81:7-14 [8834571.001]
  • [Cites] Cancer Treat Res. 1996;82:65-77 [8849944.001]
  • [Cites] Can Assoc Radiol J. 1996 Oct;47(5):335-41 [8857967.001]
  • [Cites] Clin Orthop Relat Res. 1996 Oct;(331):277-82 [8895650.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1996 Sep;58(3):177-82 [8940789.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] Mod Pathol. 1997 Feb;10(2):113-20 [9127316.001]
  • [Cites] Ann Vasc Surg. 1997 Mar;11(2):183-5 [9181776.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Int J Urol. 1997 Sep;4(5):441-6 [9354943.001]
  • [Cites] Anticancer Res. 1997 Sep-Oct;17(5B):3877-81 [9427796.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Surg Oncol. 1993 Jul;53(3):197-203 [7687315.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Eur J Cancer. 1994;30A(6):746-51 [7917531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):129-34 [7995743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):87-92 [7995772.001]
  • [Cites] J Surg Oncol. 1999 May;71(1):32-5 [10362089.001]
  • [Cites] World J Surg. 1999 Jul;23(7):670-5 [10390584.001]
  • [Cites] Tumori. 1999 Jul-Aug;85(4):259-64 [10587028.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):157-63 [10758318.001]
  • [Cites] Eur J Surg Oncol. 1992 Oct;18(5):475-80 [1426298.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):190-9 [1536134.001]
  • [Cites] Ann Surg. 1984 Aug;200(2):200-4 [6465975.001]
  • (PMID = 18521304.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395448
  •  go-up   go-down


8. Giovanis P, Garna A, Marcante M, Nardi K, Giusto M: Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity. Tumori; 2009 Jul-Aug;95(4):545-6
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ifosfamide-induced encephalopathy requires interruption of chemotherapy, intravenous hydration and administration of methylene blue.
  • Less is known about the efficacy of methylene blue in avoiding a second episode of ifosfamide-induced encephalopathy while maintaining chemotherapy with ifosfamide.
  • We report a case of a different clinical manifestation of ifosfamide-induced encephalopathy after continued ifosfamide use and despite methylene blue in a patient with retroperitoneal sarcoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Enzyme Inhibitors / therapeutic use. Ifosfamide / adverse effects. Methylene Blue / therapeutic use. Neurotoxicity Syndromes / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / physiopathology. Sarcoma / drug therapy. Sarcoma / physiopathology

  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856674.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Enzyme Inhibitors; T42P99266K / Methylene Blue; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Aurello P, Cicchini C, De Angelis R, D'Angelo F, Ramacciatos G, Valabrega S, Indinnimeo M: Synchronous and metachronous retroperitoneal sarcomas: two case reports. Anticancer Res; 2002 Jul-Aug;22(4):2409-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous and metachronous retroperitoneal sarcomas: two case reports.
  • BACKGROUND: Retroperitoneal sarcomas represent less than 1% of all diagnosed human neoplasias.
  • They are generally malignant and can infiltrate retroperitoneal structures.
  • The value of chemotherapy and radiotherapy are difficult to evaluate and the dominating factor in the outcome is the ability to resect the tumor.
  • Recurrence of sarcoma at the operative site and on peritoneal surfaces is a prominent cause of morbidity and mortality.
  • CASE REPORTS: Here we report two patients who underwent surgery for retroperitoneal sarcoma.
  • In each of them at least two primary retroperitoneal tumors were diagnosed.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Retroperitoneal Neoplasms / surgery. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174935.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Pham TH, Iqbal CW, Zarroug AE, Donohue JH, Moir C: Retroperitoneal sarcomas in children: outcomes from an institution. J Pediatr Surg; 2007 May;42(5):829-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal sarcomas in children: outcomes from an institution.
  • BACKGROUND: Retroperitoneal sarcomas are uncommon in children and tend to present as large tumors with advanced locoregional involvement of abdominopelvic structures.
  • We reviewed our institutional experience with retroperitoneal sarcomas in children.
  • MATERIALS AND METHODS: In a retrospective review of charts dating between 1975 and 2005, we identified patients younger than 18 years who were diagnosed with a histologically confirmed retroperitoneal sarcoma.
  • The common histologic types were rhabdomyosarcoma (33%) and fibrosarcoma (33%).
  • Seventy-six percent of the patients underwent primary or secondary resection, 71% received neoadjuvant and/or adjuvant chemotherapy therapy, and 38% received radiation therapy.
  • For all patients, the mean survival time was 103 +/- 16 months and the 5-year disease-specific survival rate was 62%.
  • Survival was significantly better for patients with low-grade sarcomas than for those with high-grade sarcomas (90% vs 36%, P = .008).
  • Among those who underwent an initial complete resection, 50% had a recurrence at a mean time of 88 +/- 52 months (range = 3-261 months).
  • CONCLUSIONS: Resection of retroperitoneal sarcomas can be performed safely with minimal morbidity and mortality.
  • [MeSH-major] Retroperitoneal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Child. Female. Humans. Male. Postoperative Complications. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17502193.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Liptak JM, Dernell WS, Ehrhart EJ, Rizzo SA, Rooney MB, Withrow SJ: Retroperitoneal sarcomas in dogs: 14 cases (1992-2002). J Am Vet Med Assoc; 2004 May 1;224(9):1471-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal sarcomas in dogs: 14 cases (1992-2002).
  • OBJECTIVE: To describe the clinical features, surgical and histologic findings, biological behavior, and outcome of dogs with retroperitoneal sarcomas.
  • PROCEDURES: Medical and pathology records from 1992 to 2002 of dogs with tumors originating in the retroperitoneal space were reviewed.
  • Dogs with retroperitoneal tumors originating from the adrenal glands, kidneys, or ureters were excluded.
  • Inclusion criteria included observation of a tumor arising from the retroperitoneal space during exploratory surgery or necropsy and histologic confirmation of tumor type.
  • RESULTS: Retroperitoneal sarcoma was diagnosed in 14 dogs, 2 at necropsy and 12 during exploratory surgery.
  • Hemangiosarcoma was the most common histologic diagnosis.
  • Seven dogs had regional extension of the sarcoma into adjacent organs, and 4 dogs had metastatic disease.
  • Two dogs were treated with palliative radiation therapy (1 intraoperatively and 1 postoperatively).
  • Three dogs received adjunctive chemotherapy, although none completed the targeted course because of development of local recurrence or metastatic disease.
  • Thirteen dogs died or were euthanatized as a result of the retroperitoneal sarcoma; 1 dog was alive and disease-free 410 days after surgery.
  • Median survival time was 37.5 days.
  • CONCLUSIONS AND CLINICAL RELEVANCE: In dogs, retroperitoneal sarcomas are aggressive tumors with a high rate of local recurrence and metastasis, and a poor survival time.
  • [MeSH-major] Dog Diseases / mortality. Retroperitoneal Neoplasms / veterinary. Sarcoma / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Dogs. Female. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local / veterinary. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15124889.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Nezame FS, Krarup-Hansen A, Bergenfeldt M: [Retroperitoneal sarcomas - size not decisive]. Ugeskr Laeger; 2008 Feb 18;170(8):655

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retroperitoneal sarcomas - size not decisive].
  • A 70 year-old female presented with a 40 x 40 cm unresectable liposarcoma which showed progression during chemotherapy.
  • Retroperitoneal sarcomas are notoriously "silent", and may grow to considerable size before diagnosis.
  • Management at a national "Sarcoma Unit" is essential for the prognosis.
  • [MeSH-major] Liposarcoma / pathology. Retroperitoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364162.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


13. Raut CP, Pisters PW: Retroperitoneal sarcomas: Combined-modality treatment approaches. J Surg Oncol; 2006 Jul 1;94(1):81-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal sarcomas: Combined-modality treatment approaches.
  • Retroperitoneal sarcomas (RPS) are rare tumors, accounting for approximately 15% of soft tissue sarcomas.
  • Investigators are evaluating combined-modality therapies to improve local control and disease-specific survival.
  • This review outlines current concepts and evolving treatment strategies in the diagnosis, staging, and management of RPS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Retroperitoneal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Biopsy, Needle. Combined Modality Therapy. Drug Administration Schedule. Humans. Intraoperative Care. Leiomyosarcoma / radiotherapy. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Preoperative Care. Prognosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788949.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


14. Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Le Cesne A, Blay JY, Laplanche A: Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol; 2009 Jan 1;27(1):31-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control.
  • PURPOSE: To define the optimal initial management and the best extent of surgery that would optimize margins on primary retroperitoneal sarcomas (RPS).
  • Radiotherapy and chemotherapy were administered to 121 and 145 patients, respectively.
  • The role of adjuvant treatments should be evaluated in a randomized trial in association with this optimal surgery.
  • [MeSH-major] Retroperitoneal Neoplasms / surgery. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Jan 1;27(1):6-8 [19047279.001]
  • (PMID = 19047280.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Schuetze SM, Ray ME: Adjuvant therapy for soft tissue sarcoma. J Natl Compr Canc Netw; 2005 Mar;3(2):207-13
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for soft tissue sarcoma.
  • Wide surgical excision is the backbone of therapy for localized soft tissue sarcoma and often produces excellent results.
  • Radiation therapy (external beam or brachytherapy) has been shown to reduce the risk of local recurrence of disease and should be offered to patients with large (>5 cm) or high-grade sarcomas, especially if a wide resection cannot be performed.
  • Use of preoperative versus postoperative radiation therapy should be planned, in consultation with a radiation oncologist and a surgical oncologist, before resection of the sarcoma if possible.
  • Chemotherapy using an anthracycline- and ifosfamide-based regimen may improve disease-free and overall survival rates.
  • Chemotherapy appears to be most beneficial for patients with very large (> or = 10 cm), high-grade sarcomas of the extremity who are at a high risk of experiencing distant recurrence of disease.
  • The effect of adjuvant chemotherapy on overall survival remains controversial.
  • Research is greatly needed to identify the patients who are most likely to benefit from conventional chemotherapy, improve the treatment of retroperitoneal sarcomas, and identify novel agents that may impact the natural history of high-risk soft tissue sarcoma.
  • [MeSH-major] Sarcoma / drug therapy. Sarcoma / radiotherapy. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Humans. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817030.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


16. Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, Nguyen Bui B, French Federation of Cancer Centers Sarcoma Group: Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer; 2001 Jul 15;92(2):359-68
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group.
  • BACKGROUND: Surgery is the main prognostic factor in retroperitoneal sarcoma.
  • However, despite progress, surgery alone is rarely curative, and analysis of the causes of failures and of other prognostic factors are warranted to ascertain treatment orientations.
  • METHODS: Data of patients treated from 1.80 to 12.94 for primary retroperitoneal sarcoma were extracted from the French Federation of Cancer Centers Sarcoma Group registry.
  • Multimodality treatment included surgery (150 patients), radiotherapy (92 patients), and chemotherapy (77 patients).
  • The main prognostic factors for survival were initial metastases and surgery, which represented the major treatment-linked factor.
  • CONCLUSIONS: Aggressive surgery remains mandatory in retroperitoneal sarcoma, but a randomized trial is needed to evaluate the place of radiotherapy for local control.
  • [MeSH-major] Neoplasm Recurrence, Local. Retroperitoneal Neoplasms / pathology. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11466691.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


17. Rossi CR, Casali P, Kusamura S, Baratti D, Deraco M: The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol; 2008 Sep 15;98(4):291-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The consensus statement on the locoregional treatment of abdominal sarcomatosis.
  • Abdominal sarcomatosis (AS) is a rare condition characterized by soft tissue sarcoma spreading throughout the abdomen, in the absence of extra-abdominal dissemination.
  • Retroperitoneal sarcomas, pelvic sarcomas, particularly uterine leiomyosarcoma, and gastrointestinal stromal tumors (GISTs) most frequently give rise to AS.
  • Systemic chemotherapy is the standard of care for AS from non-GIST sarcomas, but with an essentially palliative aim and major limitations.
  • Innovative targeted therapies has deeply affected the natural history of GIST, at least in prolonging significantly survival in responsive patients.
  • In this context, the notion that abdominal spread in the lack of extra-peritoneal lesions may typically occur in a number of patients, along with the dismal prognosis generally carried by AS, has prompted a few centers to perform cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • To date, the rarity of these presentations makes it difficult to evaluate the clinical results and the role of combined local-regional treatment is still a matter of debate.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / surgery. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Sarcoma / drug therapy. Sarcoma / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Consensus. Humans. Infusions, Parenteral. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726899.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


18. Deslée G, Guillou PJ, Baehrel B, Lebargy F: Malignant mesenchymoma of the pleura. Interact Cardiovasc Thorac Surg; 2003 Sep;2(3):376-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant mesenchymomas are rare soft tissue tumors of mesenchymal origin.
  • The treatment associated surgical resection, chemotherapy and radiotherapy.
  • Sixteen months after the diagnosis a metastatic retroperitoneal sarcoma with osteosarcomatous differentiation appeared without any sign of thoracic recurrence.
  • A surgical resection was performed, but a rapid retroperitoneal recurrence led to death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670075.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Thomas DM, O'Sullivan B, Gronchi A: Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. Expert Rev Anticancer Ther; 2009 Aug;9(8):1145-57
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management.
  • Retroperitoneal soft-tissue sarcomas are complex, heterogeneous cancers requiring expert multidisciplinary care.
  • They can occur anywhere in the retroperitoneal abdominal or pelvic space.
  • Usually large at presentation they present particular challenges for both local treatment and systemic control.
  • The most common adult subtypes are liposarcomas and leiomyosarcomas, followed by pleomorphic sarcoma/malignant fibros histiocytoma (an entity not always easily distinguishable from dedifferentiated liposarcoma).
  • A variety of additional histotypes may also be observed, but are uncommon in the retroperitoneum, either because of intrinsic rarity or because they are usually found in other anatomic sites.
  • Pediatric subtypes mainly comprise extraskeletal Ewing sarcoma/pPNET and alveolar rhabdomyosarcoma.
  • Chemotherapy has a limited role in the adjuvant setting for most forms of retroperitoneal sarcoma (excluding pediatric subtypes), but has an increasing role in advanced disease.
  • Novel targeted therapeutic agents that target specific amplification or translocation products offer promise for subsets of these diseases.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Animals. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Child. Combined Modality Therapy. Drug Delivery Systems. Humans. Palliative Care / methods. Radiotherapy, Adjuvant / methods

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671034.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 93
  •  go-up   go-down


20. Della Vittoria Scarpati M, Della Vittoria Scarpati G, Santini M, Vicidomini G, Parascandolo V: [Retroperitoneal pleomorphic liposarcoma. A case of survival after ten years]. Recenti Prog Med; 2004 Jan;95(1):27-9
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retroperitoneal pleomorphic liposarcoma. A case of survival after ten years].
  • Sarcomas are malignant neoplasms which can involve both soft tissues and/or bones.
  • The soft tissues sarcomas are very rare, representing about 1% of all malignant tumors.
  • Currently, surgery is the only curative therapy for soft tissues sarcomas in adult patients, with the exclusion of retroperitoneal sarcomas, which have have poor prognosis, due to look of surgical radicality and low radiotherapy and chemotherapy responsiveness.
  • In fact, chemotherapy by conventional regimens, as adriamicine plus ifosfamide or CYVADIC, allows not more than 25% of partial responses, with a median survival of 12 months.
  • [MeSH-major] Liposarcoma / therapy. Retroperitoneal Neoplasms / therapy
  • [MeSH-minor] Aged. Humans. Male. Survivors. Time Factors

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15032338.001).
  • [ISSN] 0034-1193
  • [Journal-full-title] Recenti progressi in medicina
  • [ISO-abbreviation] Recenti Prog Med
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Pisters PW, Ballo MT, Patel SR: Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol; 2002 Jul;9(6):535-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemoradiation treatment strategies for localized sarcoma.
  • BACKGROUND: Over the past 2 decades, there has been increasing interest in chemoradiation treatment strategies for patients with soft tissue sarcomas.
  • (1) the optimal route for chemotherapy administration (intra-arterial vs. intravenous);.
  • (3) the efficacy and toxicity of various intravenous and oral radiation sensitizers; and (4) the efficacy of sequential versus concurrent combined modality treatment.
  • METHODS: The English-language literature addressing chemoradiation for localized and locally advanced extremity and retroperitoneal sarcomas was reviewed.
  • In the studies that have included assessment of recurrence-free survival, preoperative chemoradiation combined with surgery has resulted in favorable local control rates, often in excess of 90% for patients with localized and locally advanced extremity sarcomas.
  • CONCLUSIONS: The toxicities and recurrence-free outcome with chemoradiation plus surgery for soft tissue sarcoma still need to be compared to these with surgery and pre- or postoperative radiation.
  • However, the generally favorable local control rates reported for chemoradiation justify continued investigation of preoperative chemoradiation strategies for localized sarcoma.
  • [MeSH-major] Neoadjuvant Therapy / methods. Sarcoma / drug therapy. Sarcoma / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Radiation-Sensitizing Agents / therapeutic use. Radiotherapy Dosage. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radiotherapy. Retroperitoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12095968.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 80168379AG / Doxorubicin
  • [Number-of-references] 37
  •  go-up   go-down


22. Bradley JC, Caplan R: Giant retroperitoneal sarcoma: a case report and review of the management of retroperitoneal sarcomas. Am Surg; 2002 Jan;68(1):52-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant retroperitoneal sarcoma: a case report and review of the management of retroperitoneal sarcomas.
  • He underwent resection of a well-differentiated liposarcoma arising from his retroperitoneum measuring 50 cm and weighing 11.7 kg (25.8 lb).
  • This is the second largest retroperitoneal soft-tissue sarcoma (RSTS) that has been reported.
  • RSTS represents 0.10 to 0.15 per cent of all malignancies but 45 per cent of all retroperitoneal tumors.
  • Diagnosis and treatment of RSTS can be extremely challenging for a general surgeon.
  • Treatment of RSTS remains surgical.
  • Multiple trials of chemotherapy and radiation therapy show no survival benefit.
  • The only successful treatment of this tumor is complete excision; 51.4 per cent of tumors can be completely excised, and 50.2 per cent of these excisions include adjacent organs.
  • With aggressive surgical therapy survival is increased to 58.0 and 39.6 per cent.
  • [MeSH-major] Liposarcoma / surgery. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12467318.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


23. Giménez de Marco B, Berné Manero JM, Bono Ariño A, Marigil Gómez MA, Esclarín Duny MA, Sanz Velez JI: [Retroperitoneal leiomyosarcoma]. Actas Urol Esp; 2001 Jul-Aug;25(7):523-6
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retroperitoneal leiomyosarcoma].
  • [Transliterated title] Leiomiosarcoma retroperitoneal.
  • We report a case of retroperitoneal leiomyosarcoma recurrence.
  • This entity is rare, < 0.2% of all tumours in humans and 25-30% of retroperitoneal sarcomas.
  • The diagnosis is usually delayed in relationship with scarce clinical signs which favorite the development of great tumour volume before diagnosis.
  • The treatment is surgical, with wide margins excision.
  • Radiotherapy and chemotherapy are not adequates for treatment of this pathological entity.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11534408.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Gutierrez JC, Perez EA, Moffat FL, Livingstone AS, Franceschi D, Koniaris LG: Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg; 2007 Jun;245(6):952-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients.
  • OBJECTIVE: : To define the prognostic significance of surgical center case volume on outcome for soft tissue sarcoma (STS).
  • Univariate analysis demonstrated significantly improved survival at HVC for high-grade tumors (median 30 months vs. 24 months, P = 0.001), lesions over 10 cm (28 months vs. 19 months, P = 0.001) and truncal or retroperitoneal sarcomas (39 months vs. 31 months, P = 0.011).
  • Limb amputation rate was lower (9.4% vs. 13.8%, P = 0.048) and radiation and chemotherapy were more frequently administered at HVC (OR = 1.54).
  • On multivariate analysis, treatment at a HVC was a significant independent predictor of improved survival (OR = 1.292, P = 0.047).
  • Patients with either large (>10 cm), high-grade or truncal/retroperitoneal tumors should be treated exclusively at a high-volume center.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Chi-Square Distribution. Female. Florida. Humans. Male. Middle Aged. Prognosis. Proportional Hazards Models. Prospective Studies. Registries. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2005 Oct;29(10):1241-4 [16136280.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):646-53 [15965732.001]
  • [Cites] JAMA. 2000 Dec 20;284(23):3028-35 [11122590.001]
  • [Cites] Surgery. 2002 Jan;131(1):6-15 [11812957.001]
  • [Cites] Ann Intern Med. 2002 Sep 17;137(6):511-20 [12230353.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4344-52 [12409334.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] J Bone Joint Surg Am. 1976 Apr;58(3):317-27 [177425.001]
  • [Cites] N Engl J Med. 1979 Dec 20;301(25):1364-9 [503167.001]
  • [Cites] Med Care. 1980 Sep;18(9):940-59 [7432019.001]
  • [Cites] Health Care Financ Rev. 1985 Fall;7(1):37-47 [10317676.001]
  • [Cites] JAMA. 1989 Jul 28;262(4):503-10 [2491412.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1485-92 [1938557.001]
  • [Cites] Chest. 1992 May;101(5):1332-7 [1582293.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):43-9 [7826160.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1208-12 [7551998.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):638-45 [7487211.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):650-5 [8642020.001]
  • [Cites] Am J Med Qual. 1996 Winter;11(4):193-7 [8972936.001]
  • [Cites] West J Med. 1996 Nov;165(5):294-300 [8993200.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):641-6 [9194456.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):504-14 [9344316.001]
  • [Cites] Am J Public Health. 1998 Mar;88(3):454-7 [9518982.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):429-38 [9742926.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):186-92 [9834415.001]
  • [Cites] CMAJ. 1999 Mar 9;160(5):643-8 [10101998.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):46-56 [10401740.001]
  • [Cites] Surgery. 1999 Aug;126(2):178-83 [10455881.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):404-11; discussion 411-3 [10493487.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4567-74 [15542808.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer Control. 2005 Jan-Feb;12(1):36-43 [15668651.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1637-43 [10764423.001]
  • (PMID = 17522521.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1876958
  •  go-up   go-down


25. Malerba M, Garofalo A: [A rare case of nerve-sheath sarcoma with rhabdomyoblastic differentiation (malignant triton tumor)]. Tumori; 2003 Jul-Aug;89(4 Suppl):246-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare case of nerve-sheath sarcoma with rhabdomyoblastic differentiation (malignant triton tumor)].
  • [Transliterated title] Un raro caso di sarcoma delle guaine nervose a differenziazione rabdomioblastica (malignant Triton tumor).
  • Malignant peripheral nerve sheath tumors (MPNST) are spindle-cell sarcomas that appear in a setting of neurofibroma or schwannoma or are associated with peripheral nerves or demonstrate nerve sheath differentiation.
  • Malignant triton tumor (MTT) is a subtype of MPNST that also contain tissue with skeletal muscle differentiation (embryonal, plemorphic and botryoid rhabdomyosarcoma).
  • Camillo-Forlanini Hospital in Rome for both a right-sided retroperitoneal paravertebral not palpable mass, incidentally detected at a follow-up MRI, and a left-sided popliteal mass, discovered at clinical evaluation.
  • Seventeen months before, when the patient underwent surgery at the same Department for both a left-sided paravertebral inferior mediastinal neurofibroma and a right-sided axillary neurofibroma, diagnosis of von Recklinghausen disease (NF1) was made, according to the criteria established by the NIH Consensus Development.
  • The popliteal mass was resected too and resulted to be a neurofibroma just like the tumors resected 17 months before when diagnosis of von Recklinghausen disease was made.
  • Sarcoma arising in anatomic site other than extremity and superficial trunk are often more difficult to control because of anatomic constraints, delayed disease presentation, proximity to neurovascular and osseous structures and toxicity for normal adjacent tissues that limits the use of adequate radiation doses.
  • Indeed, the anatomic site is an important prognostic factor in STS and the prognosis for retroperitoneal tumors is considerably worse than for extremity tumors.
  • Reported local recurrence rates for retroperitoneal sarcomas range from 40% to 80% and, in marked contrast to extremity STS, most of patients can and do die from local recurrence in the absence of metastasis.
  • In contrast to the benefit most patients with high grade soft tissue sarcomas of the extremities receive from adjuvant radiation and chemotherapy, these modalities have been of little value for retroperitoneal tumors.
  • Current chemotherapy for retroperitoneal sarcomas is ineffective.
  • Local adjuvant therapy such as intraperitoneal chemotherapy or experimental immunotherapy seems to be attractive in theory, but needs further investigations through prospective randomized multicentric trials.
  • In conclusion, to date aggressive surgical management remains the most effective modality for selected primary and recurrent retroperitoneal soft tissue sarcomas including MPNSTs and the subtype MTT.
  • Patients with incomplete resection and other risk factors such as younger age and high grade tumors may be suitable candidates for investigational adjuvant therapy.
  • [MeSH-major] Neurilemmoma / pathology. Neurofibromatosis 1 / pathology. Peripheral Nervous System Neoplasms / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Axilla. Cell Differentiation. Humans. Knee. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Muscles / pathology. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Spinal Nerve Roots / pathology. Spinal Nerve Roots / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12903608.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Cagol PP, Pasqual E, Bacchetti S: Natural history of the neoplastic locoregional disease: clinical and pathological patterns. J Exp Clin Cancer Res; 2003 Dec;22(4 Suppl):1-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A great number of locoregional treatments are currently carried out to treat a variety of locoregional neoplastic diseases.
  • Indications are the treatment of primary and metastatic liver tumors, peritoneal mesotheliomas, peritoneal spread of ovarian carcinomas, peritoneal recurrences of gastrointestinal cancers, peritoneal spread of retroperitoneal sarcomas, melanomas and sarcomas of the limbs, some primary tumors of the brain, breast, kidney, lung, bladder.
  • But to deal with locoregional therapy demands to clarify some features of these malignancies.
  • At this regard, the knowing of their natural history can be crucial to guide the choice of the correct locoregional treatment.
  • Selected patients with peritoneal neoplastic seeding, previously considered in a preterminal condition, can be considered as candidates for curative treatment, using cytoreductive surgical tecniques (16) and hyperthermic intraperitoneal chemotherapy (19).
  • In this paper the main aspects of liver metastases and peritoneal carcinomatosis natural history, two of the most frequently recognized indications for locoregional therapy, are presented.
  • [MeSH-minor] Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767897.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 20
  •  go-up   go-down


27. Willett CG: Intraoperative radiation therapy. Int J Clin Oncol; 2001 Oct;6(5):209-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiation therapy.
  • The modern use of intraoperative radiation therapy (IORT) was initiated by the studies of Abe and colleagues at the University of Kyoto.
  • Most importantly, this high dose of additional radiation treatment yields improved local control of selected tumors.
  • Treatment programs of external beam radiation therapy, surgical resection, and IORT for patients with locally advanced primary and recurrent rectal carcinoma and retroperitoneal sarcoma have yielded excellent local control and higher survival rates.
  • The future of IORT will be in the successful integration of this therapy into multimodality treatment programs of chemotherapy, external beam irradiation, and surgery for locally advanced malignancies.
  • [MeSH-major] Carcinoma / radiotherapy. Rectal Neoplasms / radiotherapy. Retroperitoneal Neoplasms / radiotherapy. Sarcoma / radiotherapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Dogs. Humans. Intraoperative Period. Male. Radiation Tolerance. Radiotherapy, High-Energy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11723741.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


28. Pirayesh A, Chee Y, Helliwell TR, Hershman MJ, Leinster SJ, Fordham MV, Poston GJ: The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature. Eur J Surg Oncol; 2001 Aug;27(5):491-7
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature.
  • AIM: Ten percent of soft tissue sarcomas (STS) arise in the retroperitoneal tissues.
  • The prognosis for patients with retroperitoneal sarcoma is poor with a 5-year survival rate between 12% and 70%.
  • METHODS: Complete follow-up data were available on 22 patients who underwent surgery for retroperitoneal STS in our institution between 1990 and 2000.
  • Patient, tumour and treatment variables were analysed including use of adjuvant therapy and survival status.
  • The tumours were seven liposarcomas, six leiomyosarcomas, three malignant fibrous histiocytomas, two rhabdomyosarcomas, two malignant schwannomas and two undifferentiated sarcomas.
  • Six primary tumours were completely excised, five patients received radiotherapy and five received chemotherapy.
  • Five patients received radiotherapy and five received chemotherapy.
  • Adjuvant therapy was not associated with higher survival rates.
  • CONCLUSION: This study re-emphasizes the poor outcome of patients with retroperitoneal STS.
  • Adjuvant radiotherapy and chemotherapy do not appear to be any proven benefit and the single most important prognostic factor is aggressive successful en bloc resection of the primary tumour.
  • [MeSH-major] Retroperitoneal Neoplasms / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / surgery. Humans. Male. Middle Aged. Neurilemmoma / surgery. Prognosis. Retrospective Studies. Sarcoma / surgery. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11504522.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 53
  •  go-up   go-down


29. Sturm N, Moulai N, Laverrière MH, Chabre O, Descotes JL, Brambilla E: Primary adrenocortical sarcomatoid carcinoma: case report and review of literature. Virchows Arch; 2008 Feb;452(2):215-9
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenocortical carcinoma (AC) mixed with a sarcoma or sarcoma-like component is exceptional, and only six cases have been detailed in the literature, three including osteo-, chondro-, or rhabdomyosarcoma components, and three others only showing a malignant spindle cell component.
  • The patient died 3 months of locoregional and distant recurrences after surgery despite apparently total tumor resection and VP16-cisplatinum chemotherapy.
  • This case underlines the necessity to identify and isolate these carcinoma's subtypes with worse prognosis and the difficulties to distinguish them from metastatic carcinomas and retroperitoneal sarcomas, in relation to the particular adrenal cortex immunoprofile.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adult. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Humans. Lymphatic Metastasis. Male. Retroperitoneal Neoplasms / diagnosis. Sarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2007 Aug;51(2):239-45 [17593212.001]
  • [Cites] J Surg Oncol. 1990 Oct;45(2):134-6 [2214792.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;415(2):161-7 [2472700.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1987 Feb;88(2):231-8 [3574283.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):626-31 [1599039.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Am J Surg Pathol. 1993 Sep;17(9):941-5 [8352379.001]
  • [Cites] J Korean Med Sci. 1997 Aug;12(4):374-7 [9288640.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • [Cites] Pathology. 1996 Nov;28(4):298-305 [9007945.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 18080137.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Perera GB, Wilson SE, Barie PS, Butler JA: Duodenocaval fistula: a late complication of retroperitoneal irradiation and vena cava replacement. Ann Vasc Surg; 2004 Jan;18(1):52-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenocaval fistula: a late complication of retroperitoneal irradiation and vena cava replacement.
  • Although migrating or ingested foreign bodies, trauma, and peptic ulcer disease are often described etiologies, 11 patients have been described who developed DCF after resection of retroperitoneal tumors, 9 of whom also had postoperative radiotherapy.
  • We report two patients who developed DCF after resection of retroperitoneal tumors followed by radiation therapy.
  • The first patient, a 56-year-old female, presented with upper gastrointestinal hemorrhage requiring transfusion caused by a duodenoprosthetic caval fistula 7 years after successful resection of a retroperitoneal leiomyosarcoma and replacement of the inferior vena cava followed by radiation and chemotherapy.
  • The second patient, a 37-year-old male who had previously undergone resection of a retroperitoneal sarcoma followed by external radiotherapy, developed massive upper and lower gastrointestinal bleeding secondary to a duodenocaval fistula.
  • The etiology, diagnosis, and treatment of DCF are analyzed with an emphasis on DCF following resection and irradiation of retroperitoneal tumors.
  • In most patients, "spontaneous" DCF have occurred as a late complication of high-dose radiation for carcinoma of the right kidney or retroperitoneal structures.
  • [MeSH-major] Aortic Diseases / etiology. Duodenal Diseases / etiology. Intestinal Fistula / etiology. Radiotherapy, Adjuvant / adverse effects. Retroperitoneal Neoplasms / radiotherapy. Sarcoma / radiotherapy. Vascular Fistula / etiology. Vena Cava, Inferior

  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14727160.001).
  • [ISSN] 0890-5096
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


31. Schwarzbach MH, Hohenberger P: Current concepts in the management of retroperitoneal soft tissue sarcoma. Recent Results Cancer Res; 2009;179:301-19
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in the management of retroperitoneal soft tissue sarcoma.
  • Soft tissue sarcomas (STS) in the retroperitoneum are usually diagnosed at the late stages.
  • Surgery is the mainstay of treatment.
  • After dissection of the retroperitoneal blood vessel, a retroperitoneal plane of dissection adjacent to the spinal foramina is established in between the layers of the abdominal wall.
  • Complete resection with tumor-free resection margins is the primary goal in retroperitoneal sarcoma surgery.
  • Preoperative assessment of pathoanatomical growth patterns with respect to retroperitoneal vascular structures--as well as to visceral and retroperitoneal organs--influences surgical strategies and thus the surgical outcome.
  • Blood vessel involvement is stratified in type I (arterial and venous involvement), type II (arterial involvement), type III(venous involvement), and type IV (no vascular involvement).
  • Adjuvant and neoadjuvant treatment options (chemotherapy, targeted therapy, and radiation therapy) are currently being investigated.
  • A prospective randomized phase III trial has shown a positive effect of neoadjuvant chemotherapy combined with regional hyperthermia in disease-free survival, response rate, and local control.
  • Subsets of liposarcomas (myxoid and round cell type) are selectively responsive to novel drugs, such as trabectedin, a DNA-binding agent.
  • Radiotherapy is applied in higher-grade locally advanced retroperitoneal STS.
  • The restricted number of patients with retroperitoneal STS and unsatisfying results in local tumor control and long-term survival indicate the need for multi-institutional cooperative studies.
  • An international effort is required to improve the evidence level on multimodal treatment algorithms.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230548.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 60
  •  go-up   go-down


32. Delord JP, Raymond E, Chaouche M, Ruffie P, Ducreux M, Faivre S, Boige V, Le Chevalier T, Rixe O, Baudin E, Pautier P, Rodier JM, Chouaki N, Escudier B, Kayitalire L, Armand JP: A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. Ann Oncol; 2000 Jan;11(1):73-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Gemcitabine and vinorelbine are active drugs with broad spectrum of activity and manageable toxicity in clinical trials.
  • PATIENTS AND METHODS: Drugs were given as 30-min infusions on day 1 and 8 (vinorelbine before gemcitabine) every 3 weeks.
  • Thirty-six patients (male:female ratio 25:11; mean age 54, PS > 60) were treated including 1 retroperitoneal sarcoma, 7 head and neck, 10 lung, 4 thyroid, 6 pancreatic, 1 bladder, 2 ovary, 2 gastric, 1 rectum, 1 unknown primary, and 1 renal cell carcinoma.
  • One toxic death due to hematologic toxicity was reported in a heavily pretreated patient who underwent prior chemotherapy and pelvic radiotherapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10690391.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


33. Froehner M, Gaertner HJ, Manseck A, Oehlschlaeger S, Wirth MP: Retroperitoneal Leiomyosarcoma Associated with an Elevated beta-HCG Serum Level Mimicking Extragonadal Germ Cell Tumor. Sarcoma; 2000;4(4):179-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal Leiomyosarcoma Associated with an Elevated beta-HCG Serum Level Mimicking Extragonadal Germ Cell Tumor.
  • Patient. A 65-year-old man was admitted with a large primary retroperitoneal tumor and an increased beta-human chorionic gonadotropin (beta-HCG) serum level.
  • A germ cell tumor was suspected; however, a computed tomography-guided biopsy failed to enable tumor classification.
  • After two courses of chemotherapy, the beta-HCG serum level had returned to the normal level and a diagnostic laparotomy with incisional biopsy was performed.
  • The immunohistochemical examination of the specimen identified the tumor as a retroperitoneal pleomorphic leiomyosarcoma.Discussion.
  • Tumor markers play only a marginal role in the work-up of patients with soft tissue sarcomas.
  • In men with suspected retroperitoneal sarcomas, however, the determination of germ cell tumor markers occasionally enables a preoperative distinguishing of primary retroperitoneal germ cell tumors with considerable consequences for management.
  • In this setting, a retroperitoneal tumor associated with a moderately elevated beta-HCG is a diagnostic dilemma, and surgeons should be aware of the pitfall of a beta-HCG-producing leiomyosarcoma in the differential diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521299.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395440
  •  go-up   go-down


34. Willett CG, Czito BG, Tyler DS: Intraoperative radiation therapy. J Clin Oncol; 2007 Mar 10;25(8):971-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiation therapy.
  • Intraoperative radiation therapy (IORT) is the delivery of irradiation at the time of an operation.
  • IORT is usually given in combination with external-beam radiation therapy with or without chemotherapy and surgical resection.
  • IORT excludes part or all dose-limiting sensitive structures, thereby increasing the effective dose to the tumor bed (and therefore local control) without significantly increasing normal tissue morbidity.
  • Despite best contemporary therapy, high rates of local failure occur in patients with locally advanced or recurrent rectal cancer, retroperitoneal sarcoma, select gynecologic cancers, and other malignancies.
  • The addition of IORT to conventional treatment methods has improved local control as well as survival in many disease sites in both the primary and locally recurrent disease settings.
  • Given newer and lower cost treatment devices, the use of IORT in clinical practice will likely grow, with increasing integration into the treatment of nonconventional malignancies.
  • [MeSH-major] Brachytherapy / methods. Electrons / therapeutic use. Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


35. Perez EA, Gutierrez JC, Moffat FL Jr, Franceschi D, Livingstone AS, Spector SA, Levi JU, Sleeman D, Koniaris LG: Retroperitoneal and truncal sarcomas: prognosis depends upon type not location. Ann Surg Oncol; 2007 Mar;14(3):1114-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal and truncal sarcomas: prognosis depends upon type not location.
  • BACKGROUND: Prognostication of truncal and retroperitoneal soft tissue sarcomas has traditionally been predicated on tumor location and grade.
  • OBJECTIVE: To compare outcomes for patients with retroperitoneal or truncal sarcomas.
  • The most common tumor types were liposarcoma (35.9%), leiomyosarcoma (30.1%), and malignant fibrous histiocytoma (MFH) (19.5%).
  • Tumor distributions were retroperitoneal (38.9%), pelvic (24.7%), abdominal (18.6%) and thoracic (17.9%).
  • Univariate analysis comparing retroperitoneal versus truncal location demonstrated no significant differences in survival.
  • Multivariate analysis of pre-treatment variables showed increasing age, grade, histopathology (leiomyosarcoma and MFH) and metastasis to be associated with worse outcomes.
  • Multivariate analysis of the treatment variables showed that surgery and negative resection margins were associated with improved survival (P < 0.001).
  • CONCLUSIONS: Successful operative resection can confer prolonged disease-free survival and cure for truncal and retroperitoneal sarcomas.
  • Future studies should focus on histological subtype rather than tumor location for truncal and retroperitoneal sarcomas.
  • [MeSH-major] Retroperitoneal Neoplasms / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Extremities / pathology. Female. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Fibrosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / drug therapy. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206483.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Wu H, Wang D: Radiation-induced alarm and failure of an implanted programmable intrathecal pump. Clin J Pain; 2007 Nov-Dec;23(9):826-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Numerous potential complications are associated with the use of programmable intrathecal (IT) drug delivery systems.
  • Here we reported an alarm and failure of an implanted programmable IT pump in a turn-off status exposed directly to radiation used for treatment of a retroperitoneal sarcoma.
  • Estimated cumulative doses to the pump were in the range of 28.5 to 36 Gy when the alarm occurred after 20 daily treatments.
  • [MeSH-minor] Dose-Response Relationship, Radiation. Humans. Male. Middle Aged. Radiotherapy Dosage. Retroperitoneal Neoplasms / therapy. Sarcoma / therapy. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18075412.001).
  • [ISSN] 0749-8047
  • [Journal-full-title] The Clinical journal of pain
  • [ISO-abbreviation] Clin J Pain
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement